Insulet (PODD) Q1 2026 earnings review
International Surge Drives a Massive Top-Line Beat
Insulet crushed Q1 expectations with a 33.9% YoY revenue surge, easily eclipsing its guided 25-27% constant currency range. The growth was spearheaded by a blistering 59.4% GAAP expansion in International Omnipod sales. Profitability followed suit, with Adjusted Operating Margin expanding 110 basis points year-over-year to 17.5%. However, the quarter wasn't flawless: an $11.7 million medical device correction hit gross margins, and Q2 guidance implies a sharp deceleration. Still, the underlying volume trends, paired with an aggressive push toward a fully closed-loop Type 2 system, paint a highly bullish picture.
🐂 Bull Case
International Omnipod revenue grew a staggering 59.4% YoY. The company is actively expanding its geographic footprint, notably entering five Middle Eastern countries to bring Omnipod 5 availability to 19 countries overall.
Despite a warranty charge impacting GAAP gross profit, Adjusted Operating Income jumped 42% YoY to $133.5M, expanding the margin by 110 basis points. The business is successfully scaling its bottom line alongside rapid revenue growth.
🐻 Bear Case
Q2 total revenue growth is guided at 20-22% in constant currency, a meaningful step down from the 30.1% achieved in Q1. International growth is also guided to decelerate to 28-30% CC from 45.2% CC.
A voluntary medical device correction required an $11.7 million warranty accrual, dragging GAAP gross margin down to 69.5%. If additional corrections emerge, it could threaten the company's 71% gross margin target.
⚖️ Verdict: 🟢
Bullish. The sheer velocity of the International segment and the steady 28% growth in the U.S. overshadow the minor warranty charge. The long-term Type 2 pipeline progress provides a massive future runway.
Key Themes
International Expansion is Accelerating Rapidly
International Omnipod is currently Insulet's most powerful growth engine. Revenue surged 59.4% YoY (45.2% in constant currency) to $242.9 million, an acceleration from the roughly 30-50% growth rates seen throughout 2025. The recent launch of Omnipod 5 and Omnipod Discover in five Middle Eastern countries indicates management is aggressively pressing this geographic advantage.
Algorithm Enhancements & Sensor Integration
Insulet is maintaining its technological edge by refining its algorithm. A new update introduces a 100 mg/dL target glucose setting (down from 110 mg/dL), which simulated data shows increases time-in-range without materially increasing hypoglycemia. Furthermore, the company completed a limited U.S. market release with Abbott's FreeStyle Libre 3 Plus, expanding its sensor connectivity moat.
Voluntary Medical Device Correction
A notable red flag in Q1 was an $11.7 million charge to Cost of Revenue due to estimated warranty costs associated with a voluntary medical device correction. This caused GAAP gross margin to dip to 69.5%, though Adjusted Gross Margin remained a healthy 71.0%. Management did not detail the exact nature of the defect in the release, making it a critical point for monitoring.
Drug Delivery Segment is Collapsing
The Drug Delivery segment is severely lagging, decelerating and effectively collapsing by 77.9% YoY to just $3.3 million. While strategically a non-core segment compared to diabetes management, the magnitude of the decline creates a consistent drag on total company optics. Guidance implies this segment will remain down ~50% for the full year.
Other KPIs
Accelerating significantly from $51.6 million in 25Q1. Operating cash flow generated a robust $113.8 million, while capital expenditures were carefully managed at $24.3 million. This cash generation supported the repurchase of 1.25 million shares during the quarter.
Up 35.7% YoY from $133.9 million. Adjusted EBITDA margin expanded to 23.9% from 23.5% a year ago, proving the company can sustain heavy R&D investments ($89.7M) and SG&A buildout ($317.2M) while still scaling profitability.
Guidance
Accelerating relative to prior expectations. Management raised the full-year outlook from the previous 20-22% range. The raise is driven by an upward revision in the International Omnipod forecast (raised to 26-28% from 24-26%).
Decelerating significantly compared to Q1's 30.1% CC growth. The U.S. Omnipod segment is guided to slow to 18-20% growth, while the International segment is guided to slow to 28-30% growth. Base effects and difficult YoY comparisons from 2025 launches are likely driving the cautious tone.
Stable. The company maintained its prior guidance for 100 basis points of margin expansion, indicating confidence in operating leverage despite the Q1 gross margin hit from the medical device correction.
Key Questions
Medical Device Correction Specifics
What exactly prompted the voluntary medical device correction in March that resulted in the $11.7 million charge, and how confident are you that this is a fully ring-fenced issue with no further warranty liability?
Q2 Deceleration Drivers
You just posted 45%+ constant currency growth internationally and 30%+ total company growth. Why does Q2 guidance assume a sudden drop to 20-22% total growth? Is this purely difficult comps, or are you seeing a slowing cadence in new patient starts?
EVOLVE Trial and T2 Trajectory
With the first participant enrolled in the EVOLVE pivotal study for the fully closed-loop system, what is the expected timeline for data readout, and how will this specific system alter your go-to-market strategy for Type 2 primary care physicians?